|

Furmonertinib Mesylate Clinical Trials

1 actively recruiting trial

Also known as: Furmonertinib Mesylate Tablets

Pipeline

Phase 1: 1

Top Sponsors

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd1

Indications

  • Advanced Non-Small Cell Lung Cancer1
  • Lung Cancer1
  • Cancer1

Other1 trial

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.